What does it take to truly connect with a big pharma? We unpacked this during a valuable discussion with MSD’s Discovery Leads Marc Levesque (Immunology), David Weinstock (Oncology), Erin Whalen (Cardiometabolic Research) and Director of BD and Licensing Koji Yashiro.
Insights
ClavystBio Conversations with MSD Discovery
Date:
4 Nov 2024 Article: 1 minCategory:
Venture buildingThey shared crucial insights into how startups can effectively engage with MSD, and what the company prioritizes in potential partnerships. A central theme emerged: solid science and a strong product are paramount.
Early engagement is key
Don't wait until you're further along to start building relationships. MSD team emphasized how proactive engagement can significantly benefit startups. They noted that many small companies miss out on valuable opportunities by not prioritizing relationship building.Prioritize Strong Science and Transparency
Clearly articulate the scientific foundation of your product and be transparent about your development process. Have a clear vision of your end product, understand the key factors that would de-risk it, define your target clinical area and indications, and identify your critical experiments.Manufacturing Matters
Don't overlook the importance of manufacturing. Inefficient or inadequate manufacturing processes can add significant delays (up to two years), potentially jeopardizing a potential deal. Robust manufacturing is a critical factor in attracting MSD's interest.- Meeting Preparation is Essential
A practical tip from the team: submit your presentation materials well in advance of your meeting (more than 24 hours). They do review the materials beforehand, which ensures a more productive and focused discussion.